AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.
体外研究
AZD-8529 potentiates the effects of glutamate at mGluR2 with an EC50 of 195 nM.
AZD-8529 does not elicit antagonist responses on mGluRs at 25 μM.
体内研究
AZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys.
AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats.
Animal Model:
Sprague-Dawley rats
Dosage:
10 mg/kg, 30 mg/kg
Administration:
Intraperitoneal injection; 2 hours before nicotine injections
Result:
Decreased the increased extracellular dopamine induced by nicotine (0.4 mg/kg, s.c.) in accumbens shell of freely-moving rats.
分子式
C24H24F3N5O3
分子量
487.47
CAS号
1092453-15-0
运输条件
Room temperature in continental US; may vary elsewhere.